Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8668512 | Journal of Clinical Lipidology | 2018 | 7 Pages |
Abstract
In patients at high cardiovascular disease risk, PCSK9 and Lp(a) are positively and dose-dependently correlated with atorvastatin dosage, whereas the presence of T2D is associated with higher PCSK9 but lower Lp(a) levels. Cholesterol ester transfer protein inhibition with torcetrapib slightly increases PCSK9 levels and decreases Lp(a) levels.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Benoit J. PhD, Francine PhD, Fatiha PhD, Weihang PhD, G. Kees MD, PhD, S. Matthijs MD, PhD, Stéphane BSc, Olivier PhD, David PharmD, Kerry-Anne PhD, David D. MD, John J.P. MD, PhD, Philip MD, PhD, Gilles PhD,